Mitigating Doxorubicin-Induced Toxicity in Breast Cancer Treatment with In Situ pH-Sensitive Carvedilol-loaded Transbilosomes: In Vitro and In Vivo Characterization
{{output}}
Doxorubicin (DRC) is widely used as a breast cancer treatment. However, its use is limited due to cardio, hepatic, and renal toxicities. Carvedilol (CVL) has emerged as a potential protective agent against DRC-induced toxicity (DIT). Despite this, CVL has a sh... ...
